Nymox Pharmaceutical Corporation

NYMX on NASDAQToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
1.78US 0.05/2.89%45,1021.25 / 2.75124.10 M

Contact Information

Nymox Pharmaceutical Corporation

Headquarters:
9900 Cavendish Boulevard,
Montréal, Québec
Canada, H4M 2V2
Tel: 800-936-9669
Fax: (514) 332-2227
Email: Send a message
Website: Visit website
For more information...
Lead: Robert Thaemlitz

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

In addition, the Company is developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA). There is a significant unmet clinical need in this patient population of elderly men. FT has completed a phase II trial in the United States in 147 men demonstrating important long-term (up to 5 year) clinical benefits in men receiving FT, including significant delay in disease progression compared to controls. The Company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States and Switzerland. The Company is in the process of relocating its headquarters from the Bahamas to Switzerland.

Paul Averback, MD, DABP - President and CEO

Erik Danielsen - Chief Financial Officer

Randall Lanham - Independent Director

Suresh Kalbag, MD

James G. Robinson - Director

Professor David Morse - Director

Richard Cutler - Director

Stock Information

Company Overview

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

In addition, the Company is developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA). There is a significant unmet clinical need in this patient population of elderly men. FT has completed a phase II trial in the United States in 147 men demonstrating important long-term (up to 5 year) clinical benefits in men receiving FT, including significant delay in disease progression compared to controls. The Company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States and Switzerland. The Company is in the process of relocating its headquarters from the Bahamas to Switzerland.

Management

Paul Averback, MD, DABP - President and CEO

Erik Danielsen - Chief Financial Officer

Board of Directors

Randall Lanham - Independent Director

Suresh Kalbag, MD

James G. Robinson - Director

Professor David Morse - Director

Richard Cutler - Director

Contact Information

Headquarters:
9900 Cavendish Boulevard,
Montréal, Québec
H4M 2V2, Canada
Telephone: 800-936-9669
Fax: (514) 332-2227
Email: Send a message
Website: Visit website